DMPA-SC* is a new, lower-dose, easy-to-use injectable contraceptive. Sayana Press, the subcutaneous DMPA product available to Family Planning 2020 (FP2020) countries, is manufactured by Pfizer Inc. and combines the drug and needle in the prefilled BD Uniject™ injection system, which was originally developed by PATH.
Before DMPA-SC, injectables could only be given using the standard vial and syringe setup and were often only able to be administered by medical workers at distant clinics with long wait times. The product’s user-friendly design makes it easier for women to access injectable contraception—including through self-injection.
For decades, PATH has championed the development and delivery of DMPA-SC to expand women’s family planning access and options. We continue to build on this experience and evidence through a number of activities, including the DMPA-SC Access Collaborative and our Self-Injection Best Practices work in Uganda.
“Many women don’t have the power to plan their families, because health centers are far away or partners refuse to let them use contraceptives. With DMPA-SC, we are giving women additional choices and access to a form of contraception that meets their needs.”— Fiona Walugembe, Project Manager, PATH Advancing Contraceptive Options, Uganda
*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate
Sayana Press is a registered trademark of Pfizer Inc. Uniject is a trademark of BD.